2023年5月15日

分享這篇文章提供的新聞Nusano標誌鹽湖城和波卡拉頓,佛羅裏達州。2023年,5月15日——Nusano Inc .公司重塑抗癌放射性同位素的生產,和藥理作用,一個世界級的合同開發和生產組織(CDMO)專門從事放射性藥物,今天宣布這兩個組織將合作推進放射性藥物的開發診斷和治療的應用。“藥理作用和Nusano分享願景為提高癌症的結果賦予下一代放射性藥物的發展,”克裏斯•勞表示Nusano的首席執行官。“我們的設施附近的大鹽湖地區創造了自然的機會協作和早期研究我們認為將有利於我們共同的客戶。”Opening the first quarter of 2025, Nusano's breakthrough production facility in West Valley City, Utah will be capable of generating multiple medical isotopes simultaneously and in large quantities to support patient care and therapeutic development. PharmaLogic Utah will be opening in Salt Lake City in the latter half of 2023, expanding its CDMO and radiopharmaceutical manufacturing capabilities in the mountain west region of the United States. PharmaLogic, in addition to their established radiopharmacy business, has focused on the growth of their cyclotron network and footprint in the CDMO space to increase access to the latest radiopharmaceutical technology for patients across the United States. The facility in Salt Lake City is one of the latest additions to the organization's portfolio. "Radioisotope supply chain stability is critical to ensuring diagnostics and treatments reach patients when they are needed," said Scott Holbrook, Chief Strategy Officer and General Manager for PharmaLogic. "Nusano's facility will bring undersupplied and rare radioisotopes online, complementing PharmaLogic's commitment to providing quality and predictability for our customers. We look forward to working together to accelerate new and emerging cancer diagnostics and treatments. " About Nusano, Inc. Nusano is a privately held medical technology company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano's proprietary ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. Nusano's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company's state-of-the-art production facility opens Q1 2025 in West Valley City, Utah. For more, please visit www.nusano.com . About PharmaLogic Holdings Corp. PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other malignancies. In addition to an established and reliable network of radiopharmacies, PharmaLogic has decades of expertise in drug development from discovery, through manufacturing and commercialization. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit: www.radiopharmacy.com . SOURCE PharmaLogic Holdings Corp